Press release
Latest Research Study on Global Pediatric HIV Infection Treatment Market Highlights Recent Trends and Future Opportunities Till 2026
Get TOC of this Report: https://www.factmr.com/connectus/sample?flag=T&rep_id=874
During the past few years, the global burden of pediatric HIV infection is becoming a challenge for the healthcare industry. According to the World Health Organization, it is estimated that around 3.2 million people were living with HIV infection at the end of 2013. Majority of children acquire HIV infection from their HIV-infected mothers during pregnancy, breastfeeding or birth. Effective treatments can reduce the risk of mother-to-child HIV transmission. However, in most of the resource-limited countries where the burden of HIV is high, the treatment for pediatric HIV infection is still not widely available. Pediatric HIV infection causes immunologic deterioration, opportunistic infections, and cancers. Diagnosis of pediatric HIV infection includes viral antibodies and virologic nucleic acid amplification tests. Viral antibodies are given to children above 18 months whereas virologic nucleic acid amplification tests (such as PCR) are performed in children less than 18 months. Combination of antiretroviral drugs is given for the treatment of pediatric HIV infection. The general pathophysiology of pediatric HIV infection is similar to that in adults however, the clinical presentations, the method of infection and treatments often differ.
Worldwide, each year, about 150,000 more children are infected (7 to 10% of all new infections) with HIV infection, and about 110,000 children die. Some of the risk factors related to the vertical transmission of HIV infection in children include high plasma viral RNA concentrations, seroconversion during pregnancy or breastfeeding, advanced maternal disease, and low maternal peripheral CD4+ T-cell counts. The most common signs of pediatric HIV infection not receiving ART include generalized lymphadenopathy, splenomegaly, oral candidiasis, hepatomegaly, CNS disease, failure to thrive, recurrent bacteremia, lymphoid interstitial pneumonitis, hepatitis, nephropathy, and others.
The market for pediatric HIV infection treatment is primarily driven by increasing prevalence of HIV infection in children. Active involvement of national and international government bodies to promote the research on HIV infection treatment drugs is responsible to drive the growth of the market during the forecast period. Moreover, increasing private-public partnerships for the research and development activities and increasing healthcare expenditure are also some of the factors driving the growth of the pediatric HIV infection treatment market. However, unavailability of treatment options in the underdeveloped countries can be the factor which can hamper the growth of global pediatric HIV infection treatment market. Moreover, the limited number of treatment options with a very high cost of branded drugs in various regions have impeded the growth of the global pediatric HIV infection treatment market.
To get complete report about Pediatric HIV Infection Treatment Market, Visit: https://www.factmr.com/report/874/pediatric-hiv-infection-treatment-market
The global market for pediatric HIV infection treatment is segmented on basis of HIV infection types, treatment, distribution channel and geography:
Segmentation by Type
Not symptomatic
Mildly symptomatic
Moderately symptomatic
Severely symptomatic
Segmentation by Treatment
Antiretroviral (ARV) drugs
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Protease Inhibitor (PI)
Integrase Strand Transfer Inhibitor (INSTI)
Others
Supportive care
Segmentation by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drugstore
e-commerce
Examples of some of the key players present in the global pediatric HIV infection treatment market are GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, ViiV Healthcare, Camber Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Apotex Inc., and others.
The report covers exhaustive analysis on:
Pediatric HIV Infection Treatment Market Segments
Pediatric HIV Infection Treatment Market Dynamics
Historical Actual Market Size, 2012 - 2016
Pediatric HIV Infection Treatment Market Size & Forecast 2016 to 2024
Pediatric HIV Infection Treatment Market Current Trends/Issues/Challenges
Competition & Companies involved
Pediatric HIV Infection Treatment Market Drivers and Restraints
Regional analysis includes
North America
Latin America
Europe
Asia Pacific
Middle East & Africa
Report Highlights:
Shifting Industry dynamics
In-depth market segmentation
Historical, current and projected industry size Recent industry trends
Key Competition landscape
Strategies of key players and product offerings
Potential and niche segments/regions exhibiting promising growth
A neutral perspective towards market performance
For Further Insights and Segment-Specific Information, Contact a Market Analyst at: https://www.factmr.com/connectus/sample?flag=AE&rep_id=874
About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Follow Us on Linkedin: https://www.linkedin.com/company/factmr/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Latest Research Study on Global Pediatric HIV Infection Treatment Market Highlights Recent Trends and Future Opportunities Till 2026 here
News-ID: 1284165 • Views: …
More Releases from Fact.MR
Insights into the Medical Gloves Market to Exceed US$ 27 Billion by 2034
The global medical gloves market (医療用手袋市場) is projected to reach a valuation of over US$ 27,141.5 million by 2034, growing from an estimated worth of US$ 11,299 million in 2024, with a forecasted compound annual growth rate (CAGR) of 9.2% until 2034.
The increasing emphasis on hygiene and infection control, particularly in healthcare environments, is driving demand for medical gloves. This demand is further fueled by stringent regulations governing healthcare standards.…
Aerial Inspection Services Market is accelerate at a CAGR of 17.5% to top US$ 9. …
The global Aerial Inspection Services is expected to reach a value of US$ 1.9 billion and is projected to grow at a compound annual growth rate (CAGR) of 17.5% over the next decade, reaching US$ 9.5 billion by 2033.Drone inspection services dominate this market, accounting for approximately 90.0% of the total aerial inspection services sector. Moreover, this segment represents a significant portion, around 25.0%, of the broader drone services market,…
Bioink Market Expected to Reach US$ 1.03 Billion by 2034 with 18.8% CAGR
In 2024, the global bioink market (バイオインク市場) is estimated at US$ 185.6 million. Forecasts project a remarkable Compound Annual Growth Rate (CAGR) of 18.8%, catapulting the demand for bioinks to reach a substantial market value of US$ 1.03 billion by 2034.
Recent years have witnessed a consistent rise in the necessity for organ replacements and tissue regeneration. Innovations in these fields are anticipated to facilitate the transformation of damaged tissues into…
Bonded Magnet Market is forecast to reach a valuation of US$ 10.9 Billion by 203 …
The Bonded Magnet Market is currently valued at around US$ 5.1 billion, and it is expected to experience substantial growth in the coming years. Projections suggest that the market will reach a valuation of US$ 10.9 billion by 2032, growing at an impressive compound annual growth rate (CAGR) of 7.8% from 2022 to 2032.
Bonded magnets play a significant role in the global magnet market, accounting for approximately 14% of its…
More Releases for HIV
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of…
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication…
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments
Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV…
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Introduction to Human Immunodeficiency Virus (HIV) Vaccines
1.1 Overview
1.2 Antiquity of HIV Vaccine
Need for the Development of HIV Vaccine
Primer of HIV inside the Body
3.1 Inclusion of HIV Virus into the System
3.2 Interaction of HIV with Host
3.3 Eradication of HIV Virus
HIV Vaccine Development Process
4.1 Introduction
…
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways…
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus.
Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral…
